Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study

doi:10.1007/s40121-021-00424-8

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 保健營養系(所) > 期刊論文 > Item 310902800/34450

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34450

標題:	Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
作者:	Liou, Bo-Huang Sun, Hsin-Yun Yang, Chia-Jui Syue, Ling-Shan Lee, Yu-Lin Tang, Hung-Jen Tsai, Hung-Chin Lin, Chi-Ying Chen, Tun-Chieh Lee, Chun-Yuan Huang, Sung-Hsi Liu, Chia-Wei Lu, Po-Liang Lin, Shih-Ping Wang, Ning-Chi Cheng, Aristine Ko, Wen-Chien Cheng, Shu-Hsing Hung, Chien-Ching
貢獻者:	Hsinchu MacKay Mem Hosp, Dept Internal Med Natl Taiwan Univ Hosp, Dept Internal Med Natl Taiwan Univ, Coll Med Natl Yang Ming Univ, Sch Med Far Eastern Mem Hosp, Dept Internal Med Natl Cheng Kung Univ Hosp, Dept Internal Med Natl Cheng Kung Univ, Coll Med Changhua Christian Hosp, Dept Internal Med Dept Internal Med, Chi Mei Med Ctr Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr Kaohsiung Vet Gen Hosp, Dept Internal Med Natl Taiwan Univ Hosp, Yunlin Branch, Dept Internal Med, Huwei Township Kaohsiung Municipal Tatung Hosp, Dept Internal Med Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan;[Chen, Tun-Chieh;Lee, Chun-Yuan;Lu, Po-Liang Kaohsiung Med Univ, Coll Med Natl Taiwan Univ Hosp, Dept Internal Med, Hsinchu Branch Natl Taiwan Univ, Dept Trop Med & Parasitol, Coll Med Taichung Vet Gen Hosp, Dept Internal Med Triserv Gen Hosp, Dept Internal Med Natl Def Med Ctr Taoyuan Gen Hosp, Dept Infect Dis, Minist Hlth & Welf Taipei Med Univ, Sch Publ Hlth
關鍵字:	Antiretroviral therapy Direct-acting antivirals End-of-treatment response Estimated glomerular filtration rate Ledipasvir Sofosbuvir Sustained virologic response
日期:	2021
上傳時間:	2023-11-11 11:53:27 (UTC+8)
出版者:	SPRINGER LONDON LTD
摘要:	Introduction While coformulated ledipasvir (90 mg)/sofosbuvir (400 mg) (LDV/SOF) is approved for the treatment of hepatitis C virus (HCV) genotype 2 (GT2) infection in Taiwan, Japan, and New Zealand, data regarding its use for HIV (Human Immunodeficiency Virus)-positive patients infected with HCV GT2 are sparse. We aimed to assess the effectiveness and tolerability of LDV/SOF for HIV-positive patients with HCV GT2 coinfection. Methods From January 2019 to July 2020, consecutive HIV-positive Taiwanese patients infected with HCV GT2 who received LDV/SOF were retrospectively included for analysis. The effectiveness was determined by sustained virologic response 12 weeks off-therapy (SVR12). Results Of the 114 patients (mean age, 38.6 years) initiating LDV/SOF during the study period, 0.9% had liver cirrhosis and 4.4% were HCV treatment-experienced. All patients had estimated glomerular filtration rate (eGFR) > 30 ml/min/1.73 m(2) and were receiving antiretroviral therapy with 98.2% having CD4 counts >= 200 cells/mm(3) and 93.9% plasma HIV RNA load < 50 copies/ml. Antiretrovirals prescribed included tenofovir alafenamide/emtricitabine in 42.1%, tenofovir disoproxil fumarate (TDF)/emtricitabine 18.4%, other nucleoside reverse transcriptase inhibitors (NRTIs) 39.5%, non-NRTIs 12.3%, protease inhibitors 13.2%, and integrase inhibitors 74.6%. All patients had undetectable plasma HCV RNA load at the end of treatment, and 96.5% achieved SVR12 in intention-to-treat analysis. The on-treatment eGFR decline was more pronounced in those receiving TDF-containing antiretroviral therapy (mean change, - 8.33 ml/min/1.73 m(2)), which was reversible after discontinuation of LDV/SOF. None of the patients interrupted LDV/SOF during the 12-week treatment course. Conclusion Similar to the response observed among HIV-negative patients, LDV/SOF is effective for HIV-positive patients coinfected with HCV GT2.
關聯:	INFECT DIS THER, v.10, n.2, pp.827-838
显示于类别:	[保健營養系(所) ] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	148	检视/开启
s40121-021-00424-8.pdf		440Kb	Adobe PDF	50	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....